1. Biosimilars in RA: A Blessing or a Curse?

3. Introduction/Overview

4. What Is a Biosimilar?

5. Differences Between Development of Generics and Biosimilar Medications

6. Clinical Development Program: Biosimilars

7. Biosimilar Outliers: "Biomimics" and "Biobetters"

8. Overview of Biosimilar Regulatory Guidelines

9. Rheumatology Biosimilars for Which Data Have Been Published or Presented

10. Biosimilars and Safety in Rheumatoid Arthritis

11. Switching, Interchangeability, and Regulatory Guidance

12. Biosimilar Infliximab (CT-P13) Is Not Inferior to Originator Infliximab: Results From 52-Wk Randomized Switch Trial in Norway

13. A Nationwide Non-Medical Switch From Originator to Biosimilar Infliximab in Patients With RA: Clinical Outcomes From the DANBIO Registry

14. Extrapolation: Sponsors Can License Biosimilars for Multiple Indications, say FDA and EMA

15. Immune Reactions to Biologic Therapeutics

16. Immunogenicity and Extrapolation of Biosimilars to Multiple Indications

17. Antibodies to Infliximab in Rituximab-Treated Rheumatic Patients Show Identical Reactivity Toward Biosimilars

18. Physician Assessment of the Value of Biosimilars to the Healthcare System

19. Shares of Expenditures for the Reimbursement of Biosimilars and Originators, 2015

20. Patient Attitudes Toward Biosimilars: Survey of Patients With IBD

21. Biosimilar Naming and Traceability

22. Biosimilars and Naming Guidelines

23. What Is Pharmacovigilance?

24. Summary and Conclusions

25. Abbreviations

26. Abbreviations (cont)